China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics